| VP-0001 |
Abraxane® (paclitaxel protein-bound particles) (Intravenous) |
|
| VP-0004 |
Adcetris® (brentuximab vedotin) (Intravenous) |
|
| VP-0007 |
Alimta® (pemetrexed) (Intravenous) |
|
| VP-0008 |
Aloxi® (palonosetron) (Intravenous) |
|
| VP-0014 |
Bevacizumab: Avastin®; Mvasi™; Zirabev™ (Intravenous) |
|
| VP-0036 |
Emend® (fosaprepitant dimeglumine) (Intravenous) |
|
| VP-0038 |
Erbitux® (cetuximab) (Intravenous) |
|
| VP-0043 |
Faslodex® (fulvestrant) (Intramuscular) |
|
| VP-0057 |
Trastuzumab: Herceptin®; Ogivri™; Kanjinti™; Trazimera™; Herzuma™; Ontruzant™ (Intravenous) |
|
| VP-0071 |
Immune Globulins (immunoglobulin) (Intravenous) |
|
| VP-0089 |
Nplate™ (romiplostim) (Subcutaneous) |
|
| VP-0092 |
Kadcyla® (ado-trastuzumab emtansine) (Intravenous) |
|
| VP-0096 |
Perjeta® (pertuzumab) (Intravenous) |
|
| VP-0100 |
Provenge® (sipuleucel-T) (Intravenous) |
|
| VP-0130 |
Bendamustine (Treanda®; Bendeka™; Belrapzo™) (Intravenous) |
|
| VP-0136 |
Vectibix® (panitumumab) (Intravenous) |
|
| VP-0137 |
Velcade® (bortezomib) (Intravenous/Subcutaneous) |
|
| VP-0148 |
Yervoy™ (ipilimumab) (Intravenous) |
|
| VP-0157 |
Kyprolis® (carfilzomib) (Intravenous) |
|
| VP-0161 |
Zaltrap® (ziv-aflibercept) (Intravenous) |
|
| VP-0184 |
Gazyva (obinutuzumab) (Intravenous) |
|
| VP-0199 |
Cyramza™ (ramucirumab) (Intravenous) |
|
| VP-0208 |
Arzerra® (ofatumumab) (Intravenous) |
|
| VP-0209 |
Keytruda® (pembrolizumab) (Intravenous) |
|
| VP-0225 |
Blincyto® (blinatumomab) (Intravenous) |
|
| VP-0234 |
Colony Stimulating Factors – Pegfilgrastim: Neulasta®; Fulphila™; Udenyca™; Ziextenzo™; Nyvepria™ (Subcutaneous) |
|
| VP-0235 |
Colony Stimulating Factors: Filgrastim (Neupogen®); Filgrastim-aafi (Nivestym™); Filgrastim-sndz (Zarxio™); Tbo-Filgrastim (Granix®) (Subcutaneous/Intravenous) |
|
| VP-0237 |
Colony Stimulating Factors: Leukine® (sargramostim) (Subcutaneous/Intravenous) |
|
| VP-0257 |
Yondelis® (trabectedin) (Intravenous) |
|
| VP-0266 |
Darzalex™ (daratumumab) (Intravenous) |
|
| VP-0268 |
Empliciti™ (elotuzumab) (Intravenous) |
|
| VP-0278 |
Tecentriq™ (atezolizumab) (Intravenous) |
|
| VP-0283 |
Sustol® (granisetron extended-release) (Subcutaneous) |
|
| VP-0295 |
Bavencio® (avelumab) (Intravenous) |
|
| VP-0301 |
Imfinzi™ (durvalumab) (Intravenous) |
|
| VP-0317 |
Besponsa (inotuzumab ozogamicin) (Intravenous) |
|
| VP-0319 |
Kymriah (tisagenlecleucel) (Intravenous) |
|
| VP-0320 |
Mylotarg (gemtuzumab ozogamicin) (Intravenous) |
|
| VP-0322 |
Rituxan Hycela™ (rituximab and hyaluronidase human) (Subcutaneous) |
|
| VP-0333 |
Yescarta™ (axicabtagene ciloleucel) (Intravenous) |
|
| VP-0336 |
Cinvanti™ (aprepitant) (Intravenous) |
|
| VP-0351 |
Bortezomib* (Intravenous Only) |
|
| VP-0363 |
Akynzeo® (fosnetupitant/palonosetron) (Intravenous) |
|
| VP-0449 |
Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk) (Subcutaneous) |
|
| VP-0482 |
Polivy™ (polatuzumab vedotin-piiq) (Intravenous) |
|
| VP-0503 |
Reblozyl® (luspatercept-aamt) (Subcutaneous) |
|
| VP-0521 |
Padcev™ (enfortumab vedotin-ejfv) (Intravenous) |
|
| VP-0528 |
Sarclisa® (isatuximab-irfc) (Intravenous) |
|
| VP-0531 |
Jelmyto™ (mitomycin) (Intra-pyelocalyceal) |
|
| VP-0532 |
Trodelvy™ (sacituzumab govitecan-hziy) (Intravenous) |
|
| VP-0535 |
Darzalex Faspro™ (daratumumab and hyaluronidase-fihj) (Subcutaneous) |
|
| VP-0547 |
Evomela® (melphalan) (Intravenous) |
|
| VP-0550 |
Zepzelca™ (lurbinectedin) (Intravenous) |
|
| VP-0553 |
Phesgo™ (pertuzumab, trastuzumab and hyaluronidase-zzxf) (Subcutaneous) |
|
| VP-0558 |
Tecartus™ (brexucabtagene autoleucel) (Intravenous) |
|
| VP-0559 |
Monjuvi™ (tafasitamab-cxix) (Intravenous) |
|
| VP-0561 |
Blenrep® (belantamab mafodotin-blmf) (Intravenous) |
|
| VP-90109 |
Rituximab: Rituxan®, Truxima®, Ruxience® (Intravenous) |
|
